A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis

OBJECTIVE: We conducted a single-centre, randomised, double-blinded, placebo-controlled phase II clinical study to test safety and efficacy of a 12-week therapy with low-dose (700 mg/daily) or high-dose (2800 mg/daily) of NAC. METHODS: Twenty-one patients (ΔF508 homo/heterozygous, FEV(1 )> 40% pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Dauletbaev, N, Fischer, P, Aulbach, B, Gross, J, Kusche, W, Thyroff-Friesinger, U, Wagner, TOF, Bargon, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352166/
https://www.ncbi.nlm.nih.gov/pubmed/19666395
http://dx.doi.org/10.1186/2047-783X-14-8-352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352166/
https://www.ncbi.nlm.nih.gov/pubmed/19666395
http://dx.doi.org/10.1186/2047-783X-14-8-352

Ejemplares similares